Countermeasures against COVID-19

NIH Pandemic-Era Grants

Pandemic Era Grants

2021

↗ Live URL (may be dead)

Document text

Principal Investigator: Andrea  Marzi
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2021
Award: $38,451
Funding agency: National Institute of Allergy and Infectious Diseases

The lab developed 2 vaccine candidates expressing the SARS-CoV-2 spike protein alone or in combination with the Ebola virus glycoprotein (EBOV GP). Hamster studies revealed that a single dose of either vaccine administered intranasally (IN) or intramuscularly (IM) protected the animals from disease after SARS-CoV-2 challenge. When we vaccinated rhesus macaques 10 days prior to SARS-CoV-2 challenge with a single dose of the VSV-SARS2-EBOV vaccine, only animals vaccinated by the IM route showed no signs of COVID-19, whereas the IN vaccinated animals did including lung lesions (Furuyama et al., mBio  in revision). Ongoing studies in mice address the longevity of the protective immune response and the influence of preexisting vector immunity on vaccine efficacy (ODonnell et al., unpublished data).
Recently we have tested the efficacy of both vaccines against infection with SARS-CoV-2 variants of concern (VOC) and could show that the vaccines are still efficacious particularly after IN administration (ODonnell et al., in preparation). In collaboration with the MEssaoudi lab (UC Irvine) we characterized the pathogenesis and transcriptional responses to VOC infection in the hamster model and revealed most gene expression changes to be associated with SARS-CoV-2 B.1.1.7 infection (ODonnell  Nature Communications - under review). 
We are also working towards an updated vaccine including an additional SARS-CoV-2 antigen into our vaccine. Preliminary studies in hamsters and mice are promising (Gourdine et al., unpublished data).
In order to expand our understanding of human cytokine responses during COVID-19, we are analyzing human serum samples collected over time from patients from Indiana. In addition, we are determining IgG responses to the original SARS-CoV-2 as well as VOC (Griffin et al., unpublished data).

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><7S Gamma Globulin><Address><Animal Diseases><Animals><B.1.1.7><Blood Serum><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 S protein><COVID-19 antigen><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID19><COVID19 S protein><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 pandemic><COVID19 public health crisis><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 virus><CV-19><CV19><CoV-2><CoV2><Collaborations><Communication><Containment><Cricetinae><Data><Data Set><Dataset><Development><Dose><EBOV><Ebola virus><Ebola-like Viruses><Gene Expression><Gene Transcription><Genetic Transcription><Glycoproteins><Hamsters><Hamsters Mammals><Human><IgG><Immune response><Immunity><Immunobiology><Immunoglobulin G><Immunological response><Immunophysiology><Indiana><Infection><Intramuscular><Intranasal Administration><Intranasal Drug Administration><Knowledge><Laboratories><Length of Life><Lesion><Longevity><Lung><Lung Respiratory System><M mulatta><M. mulatta><Macaca mulatta><Mice><Mice Mammals><Modeling><Modern Man><Molecular Virology><Murine><Mus><Nature><Pathogenesis><Patients><Preparation><RNA Expression><Research><Rhesus Macaque><Rhesus Monkey><Route><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 B.1.1.7><SARS-CoV-2 S protein><SARS-CoV-2 antigen><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 antigen><SARS-CoV2 epidemic><SARS-CoV2 pandemic><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Serum><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome related corona virus 2><Testing><Therapeutic><Time><Transcription><U.K. variant><UK variant><United Kingdom variant><Update><VSV><Vaccinated><Vaccination><Vaccines><Vesicular Stomatitis Virus><Vesicular stomatitis Indiana virus><Viral Diseases><Virus Diseases><Wuhan coronavirus><base><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 antigen><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><cytokine><developmental><ebolavirus><efficacy testing><hCoV19><host response><immune system response><immunoresponse><innovate><innovation><innovative><life span><lifespan><nCoV2><pandemic><pandemic disease><pathogenic virus><pulmonary><response><severe acute respiratory syndrome coronavirus 2 B.1.1.7><severe acute respiratory syndrome coronavirus 2 antigen><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><vaccine candidate><vaccine efficacy><variants of concern><vector><viral infection><viral pathogen><virus infection><virus pathogen><virus-induced disease>